Ipsen: Q1 sales up 16.5%

(CercleFinance.com) - Ipsen has reported Q1 2018 sales that are up 16.
5% (+23.1% excluding FX factors) at 510.3 million euros, mainly boosted by sales growth of specialty medicine.

Excluding FX factors, specialty medicine reported sales growth of 27.4%, thanks to Somatuline and an increasing contribution feom Cabometyx and Onivyde; note that family health sales only inched up 0.8%.

For FY 2018, the pharmaceutical company has confirmed its financial targets, with sales growth exceeding 16% and an operating margin of over 28%.



Copyright (c) 2018 CercleFinance.com. All rights reserved.